Latest Period
Q2 2026
Security Snapshot
Foghorn Therapeutics Inc. - Common Stock, $0.0001 par value per share (FHTX) Institutional Ownership
CUSIP: 344174107
13F Institutional Holders and Ownership History from Q4 2020 to Q2 2026
Institutions Reporting
103
Shares (Excl. Options)
44,923,240
Price
$4.88
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- FHTX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 44,923,240
- Total 13F value
- $219,219,809
- Portfolio coverage rank
- 0%
- Share change
- +489,751
- Value change
- +$2,418,810
- Number of holders
- 103
- Shares outstanding
- 58,724,855
- SEC-reported price per share
- $5.05
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- FHTX - Foghorn Therapeutics Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 344174107.
- 103 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 104 to 103 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $212,433,143 to $219,219,809.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 103 institutions filings for Q2 2026.
Security key
344174107
Latest holder period
Q2 2026
13F holders
103
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
FHTX full holder history
Foghorn Therapeutics Inc. SEC filings
Foghorn Therapeutics Inc. company facts
Foghorn Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 344174107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
FHTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Flagship Ventures Fund V, L.P. | 27% | $112,194,766 | 20,774,885 | Noubar Afeyan | 09 Jan 2026 | |||
| FMR LLC | 12% | +14% | $32,467,462 | +$5,270,605 | 6,792,356 | +19% | FMR LLC | 31 Mar 2026 |
| BIOTECHNOLOGY VALUE FUND L P | 10% | $28,042,410 | 5,866,613 | BVF PARTNERS L P/IL | 31 Mar 2026 | |||
| Flynn James E | 8.6% | $24,566,920 | 5,139,523 | Deerfield Mgmt, L.P. | 31 Mar 2026 |
As of 30 Jun 2026, 103 institutional investors reported holding 44,923,240 shares of Foghorn Therapeutics Inc. - Common Stock, $0.0001 par value per share (FHTX). This represents 76% of the company’s total 58,724,855 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
73%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Flagship Pioneering, LLC | 22% | 12,674,120 | 0% | 4% | $61,849,706 |
| BVF INC/IL | 9.9% | 5,842,000 | 0% | 0.73% | $28,508,960 |
| FMR LLC | 9.7% | 5,705,958 | -5.6% | 0% | $27,845,075 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 7.5% | 4,394,367 | 0% | 0.22% | $21,444,511 |
| BlackRock, Inc. | 4.5% | 2,626,832 | +11% | 0% | $12,818,939 |
| RAYMOND JAMES FINANCIAL INC | 4.2% | 2,489,978 | -4.3% | 0% | $12,151,093 |
| Euclidean Capital LLC | 2.7% | 1,573,761 | 0% | 1.7% | $7,679,954 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 1,494,611 | -0.03% | 0% | $7,293,702 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 910,866 | +7.4% | 0% | $4,446,091 |
| Siren, L.L.C. | 1.2% | 720,720 | 0% | 0.07% | $3,517,114 |
| STATE STREET CORP | 1.2% | 697,469 | +2.6% | 0% | $3,403,649 |
| AMERIPRISE FINANCIAL INC | 0.95% | 558,685 | +24% | 0% | $2,726,383 |
| RENAISSANCE TECHNOLOGIES LLC | 0.64% | 377,936 | -7% | 0% | $1,844,328 |
| Candriam S.C.A. | 0.53% | 313,765 | 0% | 0.01% | $1,529,700 |
| NORTHERN TRUST CORP | 0.53% | 309,775 | +12% | 0% | $1,511,703 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.52% | 305,434 | +0.55% | 0.01% | $1,490,518 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.52% | 304,432 | +19% | 0% | $1,485,628 |
| Birchview Capital, LP | 0.48% | 281,937 | +0.07% | 0.64% | $1,375,853 |
| VANGUARD FIDUCIARY TRUST CO | 0.45% | 264,422 | +9.9% | 0% | $1,290,379 |
| Qube Research & Technologies Ltd | 0.35% | 203,296 | +150% | 0% | $992,084 |
| Woodline Partners LP | 0.34% | 202,145 | +12% | 0% | $986,468 |
| B Group, Inc. | 0.34% | 200,000 | +96% | 0.55% | $976,000 |
| PANAGORA ASSET MANAGEMENT INC | 0.3% | 175,406 | +52% | 0% | $855,981 |
| GOLDMAN SACHS GROUP INC | 0.28% | 164,256 | +21% | 0% | $801,569 |
| CITADEL ADVISORS LLC | 0.27% | 158,822 | -21% | 0% | $775,051 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
23
Latest
Q2 2026
Rows shown
1-23 of 23
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 44,923,240 | $219,219,809 | +$2,418,810 | $4.88 | 103 |
| 2026 Q1 | 44,440,227 | $212,433,143 | +$11,728,970 | $4.78 | 104 |
| 2025 Q4 | 41,875,144 | $226,126,895 | +$5,631,604 | $5.40 | 93 |
| 2025 Q3 | 40,899,067 | $199,997,332 | -$252,615 | $4.89 | 86 |
| 2025 Q2 | 40,966,679 | $192,544,370 | +$2,995,463 | $4.70 | 79 |
| 2025 Q1 | 40,422,738 | $147,539,082 | +$554,807 | $3.65 | 89 |
| 2024 Q4 | 40,250,865 | $189,972,345 | +$1,515,315 | $4.72 | 86 |
| 2024 Q3 | 39,996,016 | $372,365,052 | +$3,205,361 | $9.31 | 78 |
| 2024 Q2 | 39,443,565 | $226,852,214 | +$74,393,685 | $5.75 | 71 |
| 2024 Q1 | 26,459,793 | $177,447,258 | +$1,618,684 | $6.71 | 67 |
| 2023 Q4 | 26,194,106 | $168,954,975 | -$3,389,727 | $6.45 | 59 |
| 2023 Q3 | 26,924,936 | $134,628,591 | +$778,966 | $5.00 | 61 |
| 2023 Q2 | 26,763,756 | $188,422,208 | +$3,982,788 | $7.04 | 59 |
| 2023 Q1 | 26,253,067 | $162,763,500 | +$937,198 | $6.20 | 61 |
| 2022 Q4 | 26,093,883 | $166,474,381 | -$1,442,468 | $6.38 | 63 |
| 2022 Q3 | 26,307,921 | $225,720,907 | +$12,954 | $8.58 | 60 |
| 2022 Q2 | 26,276,584 | $357,367,427 | +$18,367,020 | $13.60 | 55 |
| 2022 Q1 | 24,903,791 | $379,088,288 | +$4,677,182 | $15.23 | 57 |
| 2021 Q4 | 24,151,188 | $552,334,813 | +$1,462,679 | $22.87 | 58 |
| 2021 Q3 | 11,606,587 | $161,634,440 | +$5,200,204 | $13.93 | 44 |
| 2021 Q2 | 11,234,597 | $119,870,494 | +$2,946,090 | $10.67 | 36 |
| 2021 Q1 | 10,646,057 | $139,604,845 | -$678,194 | $13.18 | 43 |
| 2020 Q4 | 10,612,558 | $212,930,838 | +$187,364,837 | $20.27 | 45 |